Intensity Therapeutics & SAKK gets European nod to begin phase 2 INVINCIBLE-4 (SAKK/66/22) study for INT230-6 to treat ...
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, and The Swiss Group for Clinical Cancer Research SAKK (SAKK), a decentralized academic research institute, announced that the European Medicines Agency (EMA) has authorized the …